Abstract Details

Title Neuropsychologic Impact of MOGAD: A Patient Reported Outcomes Study

Topic Autoimmune Neurology

Presentation(s) P3 - Poster Session 3 (12:00 PM-1:00 PM)

Poster/Presentation
Number 050

Objective To demonstrate feasibility of PROMs to assess, quality of life (QoL), cognition, mood and fatigue in MOGAD, and to assess for associations with MOGAD phenotype, MOG-IgG titer and course.

Background Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) is an autoimmune demyelinating disease with defined phenotypes. An evaluation of the functional impact of a MOGAD diagnosis beyond clinical exam and imaging may be underappreciated. Validated patient reported outcomes measures (PROMs) to assess quality of life, cognition, fatigue and mood, have not yet been integrated into clinical practice for individuals with MOGAD.

Design/Methods Individuals > 13 years of age with MOGAD, receiving care from a neurologist at our institution were recruited. Exclusion criteria: negative serum MOG-IgG, inability to consent, lack of internet access. Surveys are electronically distributed at defined timepoints (0, 3-, 6-, 9- and 12 months). Two-way ANOVA and t-tests were performed to analyze for associations between PROMs (e.g., PROMIS10, PROMS-Cognition-Function-6a, ASQ, PHQ9, MFIS) with MOGAD characteristics (e.g., disease phenotype, serum MOG-IgG titer, treatment regimen and monophasic/relapsing course).

Results This study is ongoing, with 20 active participants at present (completion to-date: 20/20 entry, 14/20 3-month, 6/20 6-month surveys). Those with MOGAD optic neuritis (ON) report higher symptoms of depression, anxiety and cognitive difficulties, versus other phenotypes (two-way ANOVA p<0.05, respectively) at study entry. Relapsing-MOGAD is associated with increased depression and anxiety than monophasic disease (t-test, p<0.05, respectively). MOG-IgG titer and glucocorticosteroid-related toxicity occurrence were not associated with significant differences in PROMs.

Conclusions This study demonstrates feasible utilization of PROMs to assess functional domains of MOGAD patients. Individuals with MOGAD ON or CCE, or relapsing disease, endorse more depression, anxiety, and poorer visual quality of life, than other phenotypes or monophasic diseases. Further enrollment of MOGAD individuals at our and other institutions will help discern the validity of these associations with disease phenotype and course.

Authors/Disclosures
Bruna Leles Vieira de Souza, MD (Work) PRESENTER	Miss Leles Vieira de Souza has nothing to disclose.
Yihan Zhang (Brigham and Women's Hospital, Harvard Medical School)	No disclosure on file
Rebecca Salky	Rebecca Salky has nothing to disclose.
Monique Anderson, MD, PhD (Mass General Hospital)	Dr. Anderson has nothing to disclose.
Takahisa Mikami, MD (Massachusetts General Hospital)	Dr. Mikami has nothing to disclose.
Rebecca L. Gillani, MD (Massachusetts General Hospital)	The institution of Dr. Gillani has received research support from The Phyllis and Jerome Lyle Rappaport Foundation. The institution of Dr. Gillani has received research support from McCourt Foundation . The institution of Dr. Gillani has received research support from Roche.
Mattia Wruble, MD	The institution of Dr. Wruble has received research support from Alexion. The institution of Dr. Wruble has received research support from Roche.
Gabriela Romanow (Massachusetts General Hospital)	Gabriela Romanow has nothing to disclose.
Anastasia Vishnevetsky, MD (Massachusetts General Hospital)	The institution of Dr. Vishnevetsky has received research support from National MS Society. The institution of Dr. Vishnevetsky has received research support from NIH (NeuroNext).
Giovanna Manzano, MD	Dr. Manzano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gilead Sciences. Dr. Manzano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for InfuCare Rx.

��ɫ��

��ɫ��